WallStreetZenWallStreetZen

NASDAQ: BRTX
Biorestorative Therapies Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Biorestorative Therapies revenue was $401.00k for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $43.3k, down 81.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, BRTX annual revenue was $401.0k, with 175% growth year-over-year.

BRTX past revenue growth

How has BRTX's revenue growth performed historically?

Company
175.03%
Industry
497.69%
Market
20.68%
BRTX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
BRTX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
BRTX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

BRTX revenue history

Current Revenue
$401.0k
Current Earnings
-$9.0M
Current Profit Margin
-2,239.2%

Be the first to know when BRTX announces revenue.

BRTX Revenue History By Year

BRTX Yearly RevenueBRTX RevenueBRTX ChangeBRTX Revenue Growth
2024-12-31$401.00k$255.20k+175.03%
2023-12-31$145.80k$26.00k+21.70%
2022-12-31$119.80k$73.80k+160.43%
2021-12-31$46.00k-$31.00k-40.26%
2020-12-31$77.00k-$53.00k-40.77%
2019-12-31$130.00k$19.00k+17.12%
2018-12-31$111.00k$30.00k+37.04%
2017-12-31$81.00k$44.65k+122.80%
2016-12-31$36.36k-$592.56k-94.22%
2015-12-31$628.92k$212.92k+51.18%
2014-12-31$416.00k$414.32k+24,661.67%
2013-12-31$1.68k-$13.91k-89.22%
2012-12-31$15.59kN/AN/A
2011-12-31$0.00N/AN/A
2010-12-31$0.00N/AN/A
2009-12-31$0.00N/AN/A

1 of 2

Biorestorative Therapies Revenue FAQ

What was BRTX's revenue last quarter?

On Invalid Date, Biorestorative Therapies (NASDAQ: BRTX) reported Q4 2024 revenue of $43.30 thousand up 124.35% year over year. In the same quarter last year, Biorestorative Therapies's revenue was $19.30 thousand.

What was Biorestorative Therapies's revenue in 2024?

Biorestorative Therapies's annual revenue for the twelve months ending Dec 31, 2024 was $401.00 thousand, a 175.03% increase year over year.

How much does Biorestorative Therapies make in a day?

Based on Biorestorative Therapies annual revenue for the past five years, BRTX makes an average of $432.66 per day.

What was Biorestorative Therapies's annual revenue growth in the past year?

As of Q2 2025, Biorestorative Therapies's revenue has grown 175.03% year over year. This is 322.66 percentage points lower than the US Biotechnology industry revenue growth rate of 497.69%. Biorestorative Therapies's revenue in the past year totaled $401.00 thousand.

How much does Biorestorative Therapies make in a year?

Biorestorative Therapies's revenue by year for the past five years is:
  • Biorestorative Therapies's revenue for the twelve months ending Dec 31, 2024 was $401.00 thousand, a 175.03% increase year over year.
  • Biorestorative Therapies's annual revenue for Dec 31, 2023 was $145.80 thousand, a 21.7% increase from 2022.
  • Biorestorative Therapies's annual revenue for 2022 was $119.80 thousand, a 160.43% increase from 2021.
  • Biorestorative Therapies's annual revenue for 2021 was $46.00 thousand, a 40.26% decrease from 2020.
  • Biorestorative Therapies's annual revenue for 2020 was $77.00 thousand, a 40.77% decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.